Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients
Dateline City:
KENILWORTH, N.J. and CHARLOTTE, N.C.
Companies working alongside providers to develop solutions to serious public health needs
KENILWORTH, N.J. and CHARLOTTE, N.C. -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. Initially, the companies will focus on reducing fracture rates for at-risk osteoporosis pat...
Source: Merck.com - Corporate News - June 30, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer
Dateline City:
KENILWORTH, N.J. & CAMBRIDGE, Mass.
Collaboration Combines Merck’s Leadership in Immuno-Oncology with Moderna’s Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities
KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Moderna Therapeutics today announced a strategic collaboration and
license agreement to develop and commercialize nov...
Source: Merck.com - Corporate News - June 29, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK cancer Keytruda Moderna MSD Source Type: news
Merck Receives CHMP Positive Opinion for KEYTRUDA ® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Opinion Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients Whose ...
Source: Merck.com - Corporate News - June 27, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NSCLC NYSE:MRK Source Type: news
Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Dateline City:
KENILWORTH, N.J.
Opinion Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients Whose Tumors Express PD-L1
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approv...
Source: Merck.com - Corporate News - June 27, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NSCLC NYSE:MRK Source Type: news
Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its second-quarter 2016 sales and earnings conference call
with institutional investors and analysts at 8:00 a.m. EDT on Friday,
July 29. During the call, company executives will provide an overview of
Merck’s performance for the quarter.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - June 24, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
Systematic Review of 58 Publications of Real-World Use of GARDASIL ® Presented at EUROGIN Congress
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases < /p > < /div > < /div > < /di...
Source: Merck.com - Corporate News - June 16, 2016 Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News #Merck #MRK $MRK EUROGIN Gardasil MSD NYSE:MRK Source Type: news
Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress
Dateline City:
KENILWORTH, N.J.
Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
announced today that in a systematic review conducted of the global
impact and effectiveness of GARDASIL® [Human Papillomavirus
Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], substantial
reductions we...
Source: Merck.com - Corporate News - June 16, 2016 Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News #Merck #MRK $MRK EUROGIN Gardasil MSD NYSE:MRK Source Type: news
Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that researchers are scheduled to provide more than 30
scientific data presentations on the company’s established and
investigational infectious disease medicines and vaccines at the
American Society for Microbiology’s ASM Microbe 2016 meeting in Boston,
June 16-20.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - June 15, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK ASM Infectious Diseases MSD NYSE:MRK Source Type: news
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes
Dateline City:
KENILWORTH, N.J. & NEW YORK
Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction
KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in
partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase
3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an
investigational oral SGLT-2 inhibitor for the treatment of patients with
...
Source: Merck.com - Corporate News - June 11, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK $PFE Ertugliflozin MSD NYSE:MRK NYSE:PFE Source Type: news
Merck to Acquire Afferent Pharmaceuticals
Dateline City:
KENILWORTH, N.J. & SAN MATEO, Calif.
KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Afferent Pharmaceuticals announced today that the two companies have
signed a definitive agreement under which Merck will acquire this
privately held pharmaceutical company. Afferent Pharmaceuticals is a
leader in the development of therapeutic candidates targeting the P2X3
receptor for the treatment of common, poorly-managed, neurogenic
conditions....
Source: Merck.com - Corporate News - June 9, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Afferent MSD Source Type: news
Merck Statement on FDA Advisory Committee Meeting for ZINPLAVA ™ (bezlotoxumab), an Investigational Agent for Prevention of Clostridium difficile Infection Recurrence
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss ZINPLAVA™ (bezlotoxumab), an investigational agen t for prevention of ...
Source: Merck.com - Corporate News - June 9, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck Statement on FDA Advisory Committee Meeting for ZINPLAVA™ (bezlotoxumab), an Investigational Agent for Prevention of Clostridium difficile Infection Recurrence
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss ZINPLAVA™ (bezlotoxumab), an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence. The Advisory Committee agreed, with a vote of 10 to 5 with one abstention, that Merck has provided substantial evidence of the safety and effecti...
Source: Merck.com - Corporate News - June 9, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Dr. Roger M. Perlmutter, president, Merck Research
Laboratories, will present an overview of the company’s oncology program
at the 52nd Annual Meeting of the American Society of Clinical Oncology
(ASCO) in Chicago on June 6, 2016 at 5:45 p.m. CDT (6:45 p.m. EDT).
Language:
English
Contact:
...
Source: Merck.com - Corporate News - June 1, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK ASCO MSD Source Type: news
Merck Receives Positive CHMP Opinion for ZEPATIER ™ (elbasvir and grazoprevir) in the European Union
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
...
Source: Merck.com - Corporate News - May 27, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD ZEPATIER Source Type: news
Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of ZEPATIER™ (elbasvir and
grazoprevir), an investigational, once-daily, fixed-dose combination
tablet for the treatment of chronic hepatitis C virus (HCV) in adult
patients. The CHMP positive opinion will be reviewed by t...
Source: Merck.com - Corporate News - May 27, 2016 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD ZEPATIER Source Type: news
